Login to Your Account

Clinic Roundup

Monday, January 7, 2013

• Celtaxys Inc., of San Francisco, said it started a Phase I study of CTX-4430, which is designed to block pro-inflammatory enzyme leukotriene A4 hydrolase. The repeat-dose study is aimed at evaluating the safety, tolerability and pharmacokinetics of the drug and will enroll 96 subjects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription